SG10201810985XA - Tofacitinib oral sustained release dosage forms - Google Patents

Tofacitinib oral sustained release dosage forms

Info

Publication number
SG10201810985XA
SG10201810985XA SG10201810985XA SG10201810985XA SG10201810985XA SG 10201810985X A SG10201810985X A SG 10201810985XA SG 10201810985X A SG10201810985X A SG 10201810985XA SG 10201810985X A SG10201810985X A SG 10201810985XA SG 10201810985X A SG10201810985X A SG 10201810985XA
Authority
SG
Singapore
Prior art keywords
sustained release
oral sustained
dosage forms
release dosage
tofacitinib
Prior art date
Application number
SG10201810985XA
Inventor
Scott Max Herbig
Sriram Krishnaswami
Iv Joseph Kushner
Manisha Lamba
Thomas C Stock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50819757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201810985X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SG10201810985XA publication Critical patent/SG10201810985XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)

Abstract

TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. 5 No suitable figure
SG10201810985XA 2013-03-16 2014-03-12 Tofacitinib oral sustained release dosage forms SG10201810985XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361802479P 2013-03-16 2013-03-16
US201361864059P 2013-08-09 2013-08-09
US201461934428P 2014-01-31 2014-01-31

Publications (1)

Publication Number Publication Date
SG10201810985XA true SG10201810985XA (en) 2019-01-30

Family

ID=50819757

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810985XA SG10201810985XA (en) 2013-03-16 2014-03-12 Tofacitinib oral sustained release dosage forms
SG11201506103UA SG11201506103UA (en) 2013-03-16 2014-03-12 Tofacitinib oral sustained release dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201506103UA SG11201506103UA (en) 2013-03-16 2014-03-12 Tofacitinib oral sustained release dosage forms

Country Status (23)

Country Link
US (4) US9937181B2 (en)
EP (3) EP3854400A1 (en)
JP (3) JP6041823B2 (en)
KR (5) KR102213616B1 (en)
CN (2) CN111419817A (en)
AU (2) AU2014233850B2 (en)
BR (1) BR112015020453B1 (en)
CA (2) CA2905604C (en)
CY (1) CY1124007T1 (en)
DK (1) DK2968155T3 (en)
ES (1) ES2865134T3 (en)
HK (1) HK1217297A1 (en)
HU (1) HUE053911T2 (en)
IL (3) IL241400B (en)
MX (1) MX2021000550A (en)
NZ (2) NZ710792A (en)
PL (1) PL2968155T3 (en)
PT (1) PT2968155T (en)
SG (2) SG10201810985XA (en)
SI (1) SI2968155T1 (en)
TW (1) TWI619516B (en)
WO (1) WO2014147526A1 (en)
ZA (2) ZA201505468B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6041823B2 (en) 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2015198225A1 (en) * 2014-06-23 2015-12-30 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of tofacitinib
TW201618783A (en) 2014-08-07 2016-06-01 艾森塔製藥公司 Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate
CN104622827A (en) * 2015-03-05 2015-05-20 重庆华邦制药有限公司 Tofacitinib tablet and preparation method thereof
CA2987114A1 (en) * 2015-06-03 2016-12-08 Triastek, Inc. Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodibleplug
WO2016198983A1 (en) * 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20180214383A1 (en) * 2015-07-16 2018-08-02 National University Of Singapore Printing drug tablets with fully customizable release profiles for personalized medicine
JP6507272B2 (en) * 2015-07-27 2019-04-24 ユニケム ラボラトリーズ リミテッド Tofacitinib orally disintegrating tablet
US20170049774A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Sustained release oral pharmaceutical compositions of tofacitinib
US20180311247A1 (en) * 2015-10-02 2018-11-01 Gilead Sciences, Inc. Combination therapies for treating cancers
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913986YA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
MX2018012913A (en) 2016-04-22 2019-01-30 Receptor Life Sciences Inc Fast-acting plant-based medicinal compounds and nutritional supplements.
CN108066319B (en) * 2016-11-10 2022-01-14 江苏先声药业有限公司 Tofacitinib citrate enteric sustained-release pellet and preparation method thereof
CN106420648A (en) * 2016-11-22 2017-02-22 山东淄博新达制药有限公司 Tofacitinib citrate tablet and preparation method thereof
EA201892396A1 (en) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
KR20180066296A (en) * 2016-12-07 2018-06-19 서울대학교산학협력단 Pharmaceutical Composition for Preventing or Treating Hyper-inflammatory Symptoms Comprising Tofacitinib and Health Food Composition for Preventing or Improving Hyper-inflammatory Symptoms Comprising Tofacitinib
US10472366B2 (en) * 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
KR102078805B1 (en) * 2017-11-30 2020-02-19 보령제약 주식회사 Pharmaceutical Composition Comprising Tofacitinib
EP3810096A1 (en) 2018-05-24 2021-04-28 Synthon B.V. Controlled release tofacitinib compositions
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
CN108992454B (en) * 2018-06-20 2020-06-02 合肥医工医药股份有限公司 Compound pharmaceutical composition for treating skin inflammatory diseases
CN110946834B (en) * 2018-09-27 2023-03-31 四川科伦药物研究院有限公司 Tofacitinib citrate tablet and preparation process thereof
CN111150711B (en) * 2018-11-07 2023-04-07 上海博志研新药物技术有限公司 Tofacitinib controlled-release tablet, preparation method and application thereof
CN111358795A (en) * 2018-12-26 2020-07-03 浙江万晟药业有限公司 Tofacitinib citrate preparation and preparation method thereof
KR20200082006A (en) * 2018-12-28 2020-07-08 주식회사 대웅제약 Extended release formulation containing tofacitinib or pharmaceutically acceptable salts thereof as an active ingredient and the preparation method for the same
US20220249385A1 (en) * 2019-03-27 2022-08-11 Unichem Laboratories Limited Extended release composition of tofacitinib
WO2021038014A1 (en) 2019-08-29 2021-03-04 Synthon B.V. Controlled release tofacitinib compositions
IL292925A (en) * 2019-11-14 2022-07-01 Pfizer 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN110787145B (en) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 Tofacitinib citrate sustained-release tablet and preparation method thereof
CN113018273A (en) 2019-12-25 2021-06-25 上海宣泰医药科技股份有限公司 Solid preparation and preparation method and application thereof
WO2021169724A1 (en) * 2020-02-26 2021-09-02 上海博志研新药物技术有限公司 Sustained-release dosage form of tofacitinib, preparation method therefor and application thereof
JP7442347B2 (en) * 2020-03-06 2024-03-04 東京エレクトロン株式会社 Substrate processing equipment and substrate processing method
US11766438B2 (en) 2020-04-24 2023-09-26 Slayback Pharma Llc Pharmaceutical compositions of tofacitinib for oral administration
BR112022022284A2 (en) * 2020-05-18 2022-12-20 Zim Laboratories Ltd NEW COMPOSITION WITH EXTENDED RELEASE OF TOFACITINIB, ITS DERIVATIVES AND SALTS
CN113712932A (en) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 Tofacitinib citrate osmotic pump tablet and preparation method thereof
WO2022026519A1 (en) * 2020-07-28 2022-02-03 Novelstar Pharmaceuticals, Inc. Novel gastroretentive extended release dosage form
CN111728953B (en) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 Sustained release preparation of tofacitinib or salt thereof and preparation method thereof
WO2022042645A1 (en) * 2020-08-26 2022-03-03 上海博志研新药物技术有限公司 Oral sustained release composition of edaravone, preparation method, and application
CN112755000A (en) * 2021-01-21 2021-05-07 石药集团欧意药业有限公司 Tofacitinib citrate sustained-release tablet
CN113069434A (en) * 2021-03-11 2021-07-06 绍兴文理学院元培学院 Tofacitinib citrate controlled-release capsule and preparation method thereof
EP4347028A1 (en) 2021-06-04 2024-04-10 Synthon B.V. Prolonged release tofacitinib compositions
KR20230071713A (en) * 2021-11-16 2023-05-23 오즈온바이오 주식회사 Osmotic pharmaceutical formulation containing acid-sensitive inorganic compound
US20230240998A1 (en) * 2021-12-22 2023-08-03 Hikma Pharmaceuticals Usa Inc. Tofacitinib extended release formulations
WO2024042218A1 (en) 2022-08-26 2024-02-29 Synthon B.V. Prolonged release tofacitinib compositions without functional coating

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2322793A (en) 1939-08-21 1943-06-29 Robert S Drummond Gear finishing tool
US3247066A (en) 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IL91398A (en) 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
DK0621032T3 (en) * 1993-04-23 2000-10-23 Novartis Ag Medicinal product with controlled release
ES2163504T5 (en) * 1994-05-06 2008-05-16 Pfizer Inc. DOSAGE FORMS OF CONTROLLED AZITROMYCIN RELEASE.
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
EA002482B1 (en) * 1997-07-01 2002-06-27 Пфайзер Инк. Sertraline salts and sustained-release dosage forms of sertraline
FR2766708B1 (en) 1997-07-30 2000-05-05 Galenix Dev COMPOSITION CONTAINING HYDROXYPROPYLCELLULOSE, HYDROXYPROPYLMETHYLCELLULOSE AND / OR ETHYLCELLULLOSE AS DISINTEGRANTS, AND PROCESS FOR OBTAINING SAME
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DK1235830T3 (en) 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds as protein kinase inhibitors
IN190699B (en) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CA2466657C (en) * 2001-11-13 2011-02-01 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
GB0127423D0 (en) 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GT200200234A (en) 2001-12-06 2003-06-27 NEW CRYSTAL COMPOUNDS
TW200302748A (en) 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
BRPI0414082A (en) * 2003-09-02 2006-10-24 Pfizer Prod Inc Sustained-release dosage forms of ziprasidone
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513139A (en) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク Multiparticulate compositions with improved stability
BRPI0416535A (en) 2003-12-04 2007-01-09 Pfizer Prod Inc spray freezing process employing an extruder to prepare multiparticulate azithromycin compositions preferably containing a poloxamer and a glyceride
WO2006067576A1 (en) 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
WO2006081569A2 (en) * 2005-01-27 2006-08-03 Alza Corporation Oral osmotic dosage form having a high flux membrane
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
WO2007057762A2 (en) * 2005-11-16 2007-05-24 Pfizer Limited Osmotic bi-layer tablet
CN101420939A (en) 2006-04-24 2009-04-29 辉瑞产品公司 Asymmetric membranes for drug delivery devices
CN101460142A (en) * 2006-06-30 2009-06-17 阿肯色大学董事会 Extended release perforated tablet
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
WO2011039686A1 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine oral sustained release dosage forms
US8519970B2 (en) 2010-07-16 2013-08-27 Perceptive Pixel Inc. Capacitive touch sensor having correlation with a receiver
EP2481397A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
JP6041823B2 (en) 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Also Published As

Publication number Publication date
AU2014233850B2 (en) 2017-02-23
EP2968155A1 (en) 2016-01-20
IL267967B (en) 2021-05-31
KR102213616B1 (en) 2021-02-05
US20140271842A1 (en) 2014-09-18
RU2018129861A (en) 2019-03-15
KR20220151016A (en) 2022-11-11
PT2968155T (en) 2021-04-22
IL241400B (en) 2019-07-31
KR20210014763A (en) 2021-02-09
JP2014181234A (en) 2014-09-29
ZA201505468B (en) 2021-06-30
US10639309B2 (en) 2020-05-05
IL283032A (en) 2021-06-30
US20200206232A1 (en) 2020-07-02
CN105101952A (en) 2015-11-25
BR112015020453A8 (en) 2019-11-12
KR20170121332A (en) 2017-11-01
AU2017203334A1 (en) 2017-06-08
HUE053911T2 (en) 2021-07-28
NZ710792A (en) 2019-09-27
NZ751227A (en) 2020-06-26
JP2018100300A (en) 2018-06-28
CA2905604C (en) 2019-05-07
US11253523B2 (en) 2022-02-22
DK2968155T3 (en) 2021-04-19
ES2865134T3 (en) 2021-10-15
EP4249055A3 (en) 2023-12-27
BR112015020453B1 (en) 2023-03-21
KR20150131238A (en) 2015-11-24
JP2016199602A (en) 2016-12-01
SG11201506103UA (en) 2015-09-29
US20180193347A1 (en) 2018-07-12
CA3037328A1 (en) 2014-09-25
KR102151842B1 (en) 2020-09-03
CA3037328C (en) 2023-01-24
KR20200103892A (en) 2020-09-02
WO2014147526A1 (en) 2014-09-25
IL241400A0 (en) 2015-11-30
AU2014233850A1 (en) 2015-08-20
RU2674345C2 (en) 2018-12-07
BR112015020453A2 (en) 2017-07-18
US9937181B2 (en) 2018-04-10
EP2968155B1 (en) 2021-03-03
CN111419817A (en) 2020-07-17
JP6041823B2 (en) 2016-12-14
MX2021000550A (en) 2021-04-19
HUE053911T4 (en) 2021-06-28
EP3854400A1 (en) 2021-07-28
ZA201905100B (en) 2021-07-28
IL267967A (en) 2019-08-29
CN105101952B (en) 2022-06-28
EP4249055A2 (en) 2023-09-27
CA2905604A1 (en) 2014-09-25
RU2015139505A (en) 2017-04-24
TWI619516B (en) 2018-04-01
SI2968155T1 (en) 2021-08-31
US20220142927A1 (en) 2022-05-12
HK1217297A1 (en) 2017-01-06
TW201436823A (en) 2014-10-01
CY1124007T1 (en) 2022-05-27
PL2968155T3 (en) 2021-10-11
JP6314188B2 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
HK1247822A1 (en) Formulations for oral administration of active agents
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015017964A (en) Bromodomain inhibitors.
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2013001677A (en) Stable formulations of linaclotide.
HK1218884A1 (en) Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
PH12015501096A1 (en) Composition for immediate and extended release
HK1223935A1 (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
TN2015000135A1 (en) Modified release formulations for oprozomib
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
EP3500291A4 (en) Formulations for oral administration of active agents
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
MX364946B (en) Improved adjuvant system for oral vaccine adminstration.
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
MX2015013279A (en) Tofacitinib oral sustained release dosage forms.
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
MX366763B (en) PHARMACEUTICAL COMPOSITIONS OF MONTELUKAST and LEVOCETIRIZINE.
IN2013MU01330A (en)